QC-6352 is a small molecule developed to inhibit the histone demethylase 4 (KDM4) that has shown potent antitumoral activity and which has a derivative named zavondemstat that is being tested in clinical trials. Researchers from Australia recently demonstrated the antiproliferative activity of QC-6352 in glioblastoma models is independent of KDM4 blockade.
Medicines for Malaria Venture and The University of Texas System have divulged dihydroorotate dehydrogenase (DHODH) (Plasmodium falciparum and Plasmodium vivax) inhibitors reported to be useful for the treatment of malaria.
Fudan University has described dihydroorotate dehydrogenase (DHODH) inhibitors reported to be useful for the treatment of bone disorders, immunological disorders, inflammatory disorders, viral infections and cancer.
Selene Therapeutics Ltd. has identified brain permeable dihydroorotate dehydrogenase (DHODH) inhibitors reported to be useful for the treatment of epilepsy, cancer, Alzheimer’s disease, rheumatoid arthritis and multiple sclerosis.
The Institute of Physical and Chemical Research, the National Institute of Infectious Diseases Japan and Shizuoka Prefectural University have discovered prodrugs of furanocoumarin derivatives acting as dihydroorotate dehydrogenase (DHODH) inhibitors and reported to be useful for the treatment of viral infection.
Human dihydroorotate dehydrogenase (hDHODH) is a mitochondrial enzyme participating in de novo pyrimidine biosynthesis essential for T- and B-lymphocyte proliferation.
Research at RIKEN has led to the identification of furanocoumarin derivatives acting as dihydroorotate dehydrogenase (DHODH) inhibitors reported to be useful for the treatment of cancer and viral infections.
Immunic AG has identified deuterated dihydroorotate dehydrogenase (DHODH) inhibitors containing a carboxylic acid bioisostere. They are reported to be useful for the treatment of Crohn’s disease, influenza, lupus erythematosus, multiple sclerosis, psoriasis, rheumatoid arthritis, SARS-CoV-2 infection (COVID-19) and cancer, among others.
Aslan Pharmaceuticals Pte Ltd. said it inked a licensing deal with Zenyaku Kogyo Co. Ltd. for its atopic dermatitis-targeting monoclonal antibody, eblasakimab, that could reach $138.5 million in up-front and milestone payments.
Aslan Pharmaceuticals Pte Ltd. said it inked a licensing deal with Zenyaku Kogyo Co. Ltd. for its atopic dermatitis-targeting monoclonal antibody, eblasakimab, that could reach $138.5 million in up-front and milestone payments.
